• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Diagnostics for Emerging Infectious Disease Threats Volume III: Bacterial Disease

$1,995.00 – $3,990.00

Clear
SKU: KLI895749 Category: Diagnostics Market Research Pages: 108
  • Description
  • Table of Contents
  • Latest reports

Description

The recent terrorism events, in addition to the ease of travel that allows infectious diseases to spread, and technology developments drive the renewed interest in clinical and environmental infectious disease diagnostics. The combined public health and bio-terrorism markets of several bacterial and protozoan diseases are estimated to be nearly $100 million.

This report, the final volume of the Diagnostics for Emerging Infectious Disease Threats series, focuses on diagnostic testing for 11 bacterial and protozoal diseases in clinical and environmental testing:

  • Anthrax
  • Brucella spp – Brucellosis
  • Clostridium botulinim – Botulism
  • Clostridium perfringens
  • Coxiella burnetti – Q Fever
  • Staphyloccoccal Enterotoxin B
  • Tuberculosis
  • Vibrio cholerae
  • Yersinia pestis – Plague
  • Malaria
  • Chagas disease (trypanosomiasis, South American)

The technologies being used and developed in the United States and worldwide are discussed. Information has been collected from numerous industry, government, and academic sources. Sensitivity, specificity, cost, speed, and volume of testing are all factors that regulate and drive the diagnostic technology development. For many of the bacterial diseases, the availability as well as use of a diagnostic that is faster than culture, which will be defined as rapid, is new. The definition of a rapid test in this report includes dipsticks, immunoassay, and PCR methods.

For this discussion about diagnostics, infectious disease testing is classified into 2 economic segments: 1) environmental and 2) clinical. Within the clinical testing category, Brucella, Q fever, chagas, malaria, and tuberculosis are considered significant economic parts. Anthrax and plague are classified as emerging. Botulism, perfringens, cholerae, and staphyloccocal enterotoxin B (SEB) clinical testing exists.

More than 70 companies with a diagnostic or developing a diagnostic in these areas with a diverse range of technological approaches, including ELISAs, lateral flow immunoassays (dipsticks), PCR, nucleic acid sequence based assays (NASBAs), DNA hybridization, ECL, indirect hemagglutination, complement fixation, and DNA Chips.

Information for this report has been collected from various industry, government, and academic sources. Interviews with numerous industry, government, and clinical participants form the core of the information. In addition, searches of the trade, business, and clinical literature were conducted to validate conclusions and fill in background, product, and company financial data where possible.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Summary of Major Findings

CHAPTER TWO: BACTERIA AND PROTOZOA INFECTIOUS DISEASES

  • Anthrax – Bacillus anthracis
  • Brucella SPP
  • Clostridium Botulinim
  • Clostridium Perfringens
  • Q Fever
  • Staphyloccoccal Enterotoxin B
  • Tuberculosis
  • Vibrio cholerae
  • Malaria
  • Chagas Disease – Trypanosomiasis, T. cruzi

CHAPTER THREE: THE MARKETS & TECHNOLOGIES

  • Introduction
  • Environmental
  • Clinical

    • Clinical Anthrax Diagnostics
    • Brucella
    • Clostridium botulinim
    • Clostridium perfringens
    • Q Fever
    • Staphylococcal Enterotoxin B
    • Tuberculosis
    • Vibrio cholerae
    • Yersinia pestis
    • Malaria
    • Chagas Disease

CHAPTER FOUR: CONCLUSIONS AND STRATEGIC IMPLICATIONS

  • First Conclusion
  • Second Conclusion
  • Third Conclusion

CHAPTER FIVE: COMPANY PROFILES

  • Alexeter Technologies
  • Becton, Dickinson, And Co.
  • BioMerieux, Inc.
  • Bio-Quant
  • Diffchamb AB
  • Gen-Probe
  • Immuno-Biological Laboratories (IBL)
  • Microgen Bioproducts
  • New Horizon Diagnostics
  • PANBIO
  • r-Biopharm AG
  • SA Scientific
  • TechLab
  • Teco Diagnostics
  • TECRA International Pty Ltd.
  • TetraCore Technologies
  • V.I. Technologies, Inc.

APPENDIX A: COMPANY DIRECTORY

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Summary of Emerging Infectious Disease Testing Market, 2001-2008

CHAPTER TWO: THE MARKETS AND TECHNOLOGIES

  • Table 2-1: Number of TB Cases (All Forms) per WHO Region in 2000
  • Table 2-2: Number of TB Cases (All Form) for 22 High-Burden Countries
  • Table 2-3: Eastern Mediterranean Region Number of Notified Tuberculosis Cases, 1998-2002
  • Table 2-4: Eastern Mediterranean Region Number of Notified Tuberculosis Cases by Country 2000-2002
  • Table 2-5: Cholera Cases in the Americas 1991-2000
  • Table 2-6: Cholera Outbreak Cases by Country 1996-2003
  • Table 2-7: Confirmed Malaria Cases in 2001
  • Table 2-8: WHO European Region Malaria Confirmed Cases 1991-2002
  • Table 2-9: WHO European Region Malaria Confirmed Cases by Country, 2000-2002
  • Table 2-10: Confirmed Malaria Cases in Top Nine European Regions & Countries 2000-2002
  • Table 2-11: Eastern Mediterranean Region Severe Malaria Countries Estimate of Cases
  • Table 2-12: WHO Roll Back Malaria Eastern Mediterranean Region Number of Confirmed Cases 2000-2002
  • Table 2-13: Number of Laboratory Confirmed Malaria Cases Southeast Asia 1996-2001

CHAPTER THREE: CONCLUSIONS AND STRETEGIC IMPLICATIONS

  • Table 3-1: Emerging Infectious Disease Testing Market Revenue by Testing Type 2001-2008
  • Table 3-2: Environmental Bio-Threat Diagnostic Revenues by Method 2001-2008
  • Table 3-3: Environmental Bio-Defense Lateral Flow Immunoassay Systems
  • Table 3-4: Commercial HHA Anthrax Tests – Survey 1
  • Table 3-5: Commercial HHA Anthrax Tests – Survey 2
  • Table 3-7: Number of Counties, Parishes, or Independent Cities in the United States by State
  • Table 3-8: Relative Limits of Detection of Selected Identification Technologies for Bacillus anthracis
  • Table 3-9: Environmental Bio-Defense DNA Systems
  • Table 3-10: Clinical Emerging Infectious Disease Testing Revenue by Disease 2001-2008
  • Table 3-11: Antrax Test Manufacturers
  • Table 3-12: Brucella Test Kits and Manufacturers by Geographic Region
  • Table 3-13: SEB Antibody Tests
  • Table 3-14: Tuberculosis Antibody Rapid Diagnostics
  • Table 3-15: Tuberculosis Nucleic Acid Diagnostic Methods
  • Table 3-16: Clinical Vibrio cholerae Diagnostics
  • Table 3-17: Number of Laboratory Confirmed Malaria Cases by Region, 1999-2002
  • Table 3-18: Number of Laboratory Confirmed Malaria Cases Southeast Asia, 1996-2001
  • Table 3-19: Southeast Asia Malaria Estimate vs. Laboratory Confirmed Cases
  • Table 3-20: Eastern Mediterranean Region Estimated Cases vs. Laboratory Confirmed Cases
  • Table 3-21: Available Malaria Antigen & Antibody RDTs
  • Table 3-22: Developing Malaria RDTs
  • Table 3-23: Number of Latin America Blood Bank Samples Screened for T. cruzi 1994-2002
  • Table 3-24: Percentage of Latin America Blood Bank Samples Screened for T. cruzi 1994-2002
  • Table 3-25: Number of Blood Bank Donations in Latin America 1994-2000
  • Table 3-26: Chagas Diagnostic Tests
  • Table 3-27: Developing Chagas Diagnostics

 

    Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition
    May 13, 2025
    In Vitro Diagnostic (IVD) Trends and Market Update, 2025
    April 7, 2025
    In Vitro Diagnostics Business Outlook, 2025 (6 Issues)
    April 3, 2025
    Molecular Diagnostics Quarterly Datastream, 2025
    April 2, 2025

Related products

  • Placeholder image

    Diagnostics for Emerging Infectious Disease Threats, Volumes I – III

    $3,995.00 – $7,990.00
  • Placeholder image

    Cell-Based Diagnostics: Technology, Applications, and Markets

    $3,500.00 – $7,000.00
  • Placeholder image

    Clinical Diagnostics in India – Market Sector Analyses and Participant Directory

    $4,500.00 – $9,990.00
  • Placeholder image

    Molecular Diagnostics for Pharmacogenetic Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Diagnostics for Emerging Infectious Disease Threats, Volumes I – IIIU.S. Market for Molecular Diagnostics, 2nd Edition
Scroll to top